Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL612853 Target Snapshot

Entamoeba histolytica · ORGANISM · Entamoeba histolytica

Back to Search Search this target Browse approvals Evidence Card
2,044Compounds
182Assays
16Approved Drugs
2,335.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Entamoeba histolytica as ChEMBL target CHEMBL612853. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Entamoeba histolytica
ORGANISM · Entamoeba histolytica
As of 2026-09-13
ChEMBL target ID
CHEMBL612853
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Entamoeba histolytica still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameEntamoeba histolytica
Target TypeORGANISM
OrganismEntamoeba histolytica
ChEMBL ↗ NCBI Taxonomy ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelEntamoeba histolytica
UniProt AccessionN/A

Entamoeba histolytica

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Entamoeba histolytica.

Review nameEntamoeba histolytica
OrganismEntamoeba histolytica
Clinical Profile

Clinical Phase Distribution

16
Approved
1
Phase III
2
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC502,235.0
EC50100.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1502 8.59 IC50 2.6 Approved
CHEMBL224742 8.3 IC50 5.012 Preclinical
CHEMBL69086 8.3 IC50 5.0 Preclinical
CHEMBL227086 8.22 IC50 6.026 Preclinical
CHEMBL309135 8.15 IC50 7.0 Preclinical
CHEMBL56179 8.1 IC50 8.0 Preclinical
CHEMBL1170756 8.05 IC50 9.0 Preclinical
CHEMBL4206155 8.04 IC50 9.2 Preclinical
CHEMBL376814 8.0 IC50 10.0 Preclinical
CHEMBL56234 7.96 IC50 11.0 Preclinical
Distribution

pChEMBL Value Distribution

351
5.0
332
5.5
122
6.0
67
6.5
70
7.0
20
7.5
10
8.0
1
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

NITAZOXANIDE
CHEMBL1401
Approved 2002
Properties Compare Identifier
PANTOPRAZOLE
CHEMBL1502
Approved 2000
Properties Compare Identifier
RABEPRAZOLE
CHEMBL1219
Approved 1999
Properties Compare Identifier
LANSOPRAZOLE
CHEMBL480
Approved 1995
Properties Compare Identifier
OMEPRAZOLE
CHEMBL1503
Approved 1989
Properties Compare Identifier
METRONIDAZOLE
CHEMBL137
Approved 1963
Properties Compare Identifier
Assay Landscape

Assay Landscape

182
Total Assays
1,050
Tested Compounds
1
Assay Types
Functional — 182 assays, 1,050 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 161 957 5.6
assay format 21 93 5.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine